The drugmaker could not produce statistically significant data on whether the nation’s most prescribed COVID-19 treatment was effective in reducing the risk of hospitalizations and deaths, according to a June 14 news release.
The results hit a snag in Paxlovid’s already murky progress, which recently faced discrepancies over rebound symptoms. The CDC warned May 25 symptoms could reappear between two to eight days after testing negative, while the Mayo Clinic said June 14 that the risk is rare.
The company said in the release that it plans to continue testing Paxlovid’s efficacy in high-risk populations.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.